Immunic (IMUX) Total Liabilities (2013 - 2026)

Immunic (IMUX) has 14 years of Total Liabilities data on file, last reported at $38.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 49.25% year-over-year to $38.5 million; the trailing twelve-month figure through Mar 2026 stood at $38.5 million (up 49.25% YoY), and the FY2025 full-year result was $30.7 million, up 36.93% from the prior year.
• Total Liabilities climbed to $38.5 million in Q1 2026, from $30.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $38.5 million in Q1 2026 to a low of $10.8 million in Q2 2022.
• A 5-year average of $21.9 million and a median of $22.4 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities slumped 30.78% in 2022 and soared 80.31% in 2023, its largest moves.
• Tracing IMUX's Total Liabilities over 5 years: stood at $14.1 million in 2022, then soared by 80.31% to $25.4 million in 2023, then slipped by 11.55% to $22.4 million in 2024, then jumped by 36.93% to $30.7 million in 2025, then advanced by 25.33% to $38.5 million in 2026.
• Business Quant data shows IMUX's Total Liabilities at $38.5 million in Q1 2026, $30.7 million in Q4 2025, and $30.2 million in Q3 2025.